SH3PXD2A

Across TCGA pan-cancer cohorts, SH3PXD2A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH3PXD2A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher SH3PXD2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH3PXD2A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THCA, UCEC, and SKCM are the cancer types where SH3PXD2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.193	0.833	<.001	13	view →
UCEC	DFS	Median	All	0.907	0.615	.021	10	view →
SKCM	DFS	Median	All	1.000	0.209	.016	4	view →
LUSC	DFS	Median	All	1.000	0.752	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH3PXD2A–THCA (DFS)

Open the THCA breakdown →